Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.

All data generated or analysed during this study are included in this article or available from the first author or the corresponding author upon request. The study protocol and consent forms were approved by the institutional review board at each site and the Ministry of Food and Drug Safety in South Korea. All procedures were carried out in accordance with the principles of the Declaration of Helsinki (revised in 2013; World Medical Association) and the Good Clinical Practice guidelines of the International Conference of Harmonization. All authors vouch for the adherence of the trial to the protocol and the accuracy and integrity of the data. This study is registered with clinicaltrials.gov, number NCT02840539. All patients provided written informed consent. This study was registered with ClinicalTrials.gov identifier NCT02840539 on July 21, 2016. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.